Skip to content

CGM vs. POCT to evaluate the effect of hyperglycemia and glycemic variability on prognosis in patients with novel coronavirus pneumonia (COVID-19) and comorbidities

CGM vs. POCT in patients with COVID-19 and comorbidities

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059733
Enrollment
Unknown
Registered
2022-05-10
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Experimental group:CGM
Control group:POCT

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Severe and critical patients who meet the requirements of the ninth edition of the new coronavirus pneumonia diagnosis and treatment plan: (1) Heavy duty: 1) One of the following conditions occurs: shortness of breath, respiratory rate (RR) >= 30 times/min; resting state, refers to oxygen saturation 50% within 24-28 hours and is managed as severe; (2) Critically ill (meet any one): Respiratory failure and mechanical ventilation are required; shock occurs; combined with other organ failure requires ICU monitoring and treatment; 2. New coronary pneumonia patients with chronic underlying diseases.

Exclusion criteria

Exclusion criteria: Those who have been enrolled in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
mortality;

Secondary

MeasureTime frame
mean glucose level;Time in blood sugar target range;

Countries

China

Contacts

Public ContactWei Wang

Shanghai Sixth People's Hospital

drwangwei3037@126.com+86 18930173816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026